文献速递泌尿男性生殖肿瘤

循环游离DNA指导PARP抑制剂治疗前列腺癌

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
PubMed 文献 · Cancer Discov · 2017-04-27

本文报告了转移性前列腺癌II期试验(TOPARP-A)中奥拉帕利治疗期间系列循环游离DNA(cfDNA)的靶向和全外显子测序结果。cfDNA浓度下降与结局独立相关(第8周总生存HR 0.19;95%CI 0.06-0.56;P=0.003),所有肿瘤组织体细胞DNA修复突变均可在cfDNA中检出,缓解患者中体细胞突变等位基因频率选择性下降(χ2P<0.001)。疾病进展时出现多个亚克隆异常,使胚系和体细胞DNA修复突变(BRCA2、PALB2)回复阅读框,成为耐药机制。

要点

  • cfDNA浓度下降与转移性前列腺癌患者结局独立相关(第8周总生存HR 0.19)。
  • 所有肿瘤组织体细胞DNA修复突变均可在cfDNA中检出。
  • 缓解患者中体细胞突变等位基因频率选择性下降(χ2P<0.001)。

核心结论

  • 这些数据支持液体活检作为转移性前列腺癌的预测、预后、疗效和耐药生物标志物。

研究设计与样本

  • 在研究者发起的奥拉帕利II期试验(TOPARP-A)中,对转移性前列腺癌患者治疗期间系列采集的循环游离DNA(cfDNA)样本进行靶向和全外显子测序,分析为前瞻性计划。

主要发现

  • cfDNA浓度下降在多变量分析中与结局独立相关(第8周总生存HR 0.19;95%CI 0.06-0.56;P=0.003)。
  • 所有肿瘤组织体细胞DNA修复突变均可在cfDNA中检出。
  • 缓解患者中体细胞突变等位基因频率选择性下降(χ2P<0.001)。
  • 在奥拉帕利缓解后疾病进展时,出现多个亚克隆异常,使胚系和体细胞DNA修复突变(BRCA2、PALB2)回复阅读框,成为耐药机制。
  • 这些分析提供预测、预后、疗效和耐药数据,疾病进展时首次可检出「二次打击」突变,提示治疗选择压力下的克隆演化和铂类耐药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity associating with homologous recombination DNA repair defects. We now report targeted and whole-exome sequencing of serial circulating cell-free DNA (cfDNA) samples collected during this trial. Decreases in cfDNA concentration independently associated with outcome in multivariable analyses (HR for overall survival at week 8: 0.19; 95% CI, 0.06-0.56; P = 0.003). All tumor tissue somatic DNA repair mutations were detectable in cfDNA; allele frequency of somatic mutations decreased selectively in responding patients (χ2P < 0.001). At disease progression, following response to olaparib, multiple subclonal aberrations reverting germline and somatic DNA repair mutations (BRCA2, PALB2) back in frame emerged as mechanisms of resistance. These data support the role of liquid biopsies as a predictive, prognostic, response, and resistance biomarker in metastatic prostate cancer.Significance: We report prospectively planned, serial, cfDNA analyses from patients with metastatic prostate cancer treated on an investigator-initiated phase II trial of olaparib. These analyses provide predictive, prognostic, response, and resistance data with "second hit" mutations first detectable at disease progression, suggesting clonal evolution from treatment-selective pressure and platinum resistance. Cancer Discov; 7(9); 1006-17. ©2017 AACR.See related commentary by Domchek, p. 937See related article by Kondrashova et al., p. 984See related article by Quigley et al., p. 999This article is highlighted in the In This Issue feature, p. 920.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Goodall J, Mateo J, Yuan W, et al. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017. PMID: 28450425. doi:10.1158/2159-8290.CD-17-0261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。